A Open Multi-center Clinical Study on Cefotaxime Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary Tract Infection
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2,032
- 主要终点
- Number of Participants With Adverse Events
研究概览
简要总结
In the proposed study, the investigators plan to evaluate the efficacy and safety of Cefotaxime sodium and sulbactam sodium for injection (2:1)for the treatment of respiratory and urinary tract acute bacterial infection under the widely used in clinical conditions.
详细描述
Cefotaxime is a third-generation cephalosporins.Cefotaxime sodium and sulbactam sodium for injection (2:1)plays a therapeutic role by the former inhibiting bacterial cell wall synthesis by irreversible competitive inhibition of β-lactamase.The antimicrobial effect of cefotaxime can be enhanced by the two combined.The compound specifically aims to the mechanism of bacterial resistance, extending the life of cefotaxime in the treatment-resistant pathogen infections.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients who qualify for moderate and severe acute respiratory or urinary tract bacterial infection of acute bacterial infections need for systemic antibiotic therapy.
- •Age>18 years old, Gender: both
- •Women of childbearing age were to be negative pregnancy test and agree to take contraceptive measures during the trial;
- •patients were volunteers and signed informed consent form;
- •patients did not participate in other clinical trials.
排除标准
- •Patients were hypersusceptibility to the test drug or other penicillins ,β-lactamase inhibitor
- •Pregnant and Lactating women
- •Patients have severe liver,kidney,cardiovascular,cerebrovascular,endocrine and hematopoietic system of primary diseases and that of immunodeficiency,advanced cancer or mental illness.
- •Patients who were complicated by other diseases and thought to affect efficacy evaluations or poor compliance.
研究组 & 干预措施
xinzhijun
1.5-3.0g,iv,bid or tid for 5-12 days
干预措施: xinzhijun (Drug)
结局指标
主要结局
Number of Participants With Adverse Events
时间窗: day0-day22-28
the incidence(%)of allergies, skin rashes, shock,death, etc.
次要结局
- Clinical Effect(at weeks 4,day22-28)